CTI BioPharma Corp.

About CTI BioPharma Corp.

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.

CTI BioPharma focuses on the acquisition, development and commercialization of therapies for blood-related cancers that offer unique benefits to patients.

https://www.ctibiopharma.com

CTIC United States

5.78USD0.015 (-0.26%)

• At close Thu Oct 06 2022

NasdaqCM exchange

Sector: Healthcare

Industry: Biotechnology

Location United States, Seattle

Grade: ADF

700,454,848 USD
MARKET CAP
.
PE
0.912
BETA (5y)
-0.737
EPS

Profits

for 5 years
102%
for 3 years
386%
for 2 years
74%
for last year
182%
for this year
0%
CTI BioPharma Corp.
© 2023 avazzy.com. All rights reserved
Make with 🤎 and ☕ for you!

Investing involves risk, including possible loss of principal.

The strategies discussed are strictly for illustrative and educational purposes and are not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. There is no guarantee that any strategies discussed will be effective.

International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation and the possibility of substantial volatility due to adverse political, economic or other developments. These risks often are heightened for investments in emerging/ developing markets or in concentrations of single countries.